middle.news
Radiopharm Theranostics Advances Multiple Trials Amid $14.9M Quarterly Cash Burn
9:44am on Thursday 23rd of April, 2026 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Advances Multiple Trials Amid $14.9M Quarterly Cash Burn
9:44am on Thursday 23rd of April, 2026 AEST
Key Points
90% concordance in RAD 101 Phase 2b imaging trial
RAD 202 Phase 0/1 data show tumor uptake and safety
Two new First-In-Human trials initiated for RV-01 and RAD 402
Quarter-end cash balance $19.2 million, down from $34.5 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE